Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 368Uterine Cervical Neoplasms 144Carcinoma, Ovarian Epithelial 108Fallopian Tube Neoplasms 105Endometrial Neoplasms 99Breast Neoplasms 82Carcinoma, Non-Small-Cell Lung 70Neoplasms 55Stomach Neoplasms 49Melanoma 44Colorectal Neoplasms 44Neoplasm Metastasis 40Pancreatic Neoplasms 37Carcinoma, Renal Cell 36Triple Negative Breast Neoplasms 33Recurrence 31Squamous Cell Carcinoma of Head and Neck 28Lung Neoplasms 28Uterine Neoplasms 25Sarcoma 25Urinary Bladder Neoplasms 24Peritoneal Neoplasms 24Uterine Cervical Dysplasia 23Prostatic Neoplasms 23Colonic Neoplasms 23Esophageal Neoplasms 22Head and Neck Neoplasms 21Carcinoma, Transitional Cell 18Testicular Neoplasms 16Small Cell Lung Carcinoma 16

Interventions

temsirolimus 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Recurrent Uterine Sarcoma × Gynecologic × Clear all
NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡